Skip to Content
Merck
  • Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells.

Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells.

Cell cycle (Georgetown, Tex.) (2014-02-21)
Yuko Murakami-Tonami, Satoshi Kishida, Ichiro Takeuchi, Yuki Katou, John M Maris, Hitoshi Ichikawa, Yutaka Kondo, Yoshitaka Sekido, Katsuhiko Shirahige, Hiroshi Murakami, Kenji Kadomatsu
ABSTRACT

The condensin complex is required for chromosome condensation during mitosis; however, the role of this complex during interphase is unclear. Neuroblastoma is the most common extracranial solid tumor of childhood, and it is often lethal. In human neuroblastoma, MYCN gene amplification is correlated with poor prognosis. This study demonstrates that the gene encoding the condensin complex subunit SMC2 is transcriptionally regulated by MYCN. SMC2 also transcriptionally regulates DNA damage response genes in cooperation with MYCN. Downregulation of SMC2 induced DNA damage and showed a synergistic lethal response in MYCN-amplified/overexpression cells, leading to apoptosis in human neuroblastoma cells. Finally, this study found that patients bearing MYCN-amplified tumors showed improved survival when SMC2 expression was low. These results identify novel functions of SMC2 in DNA damage response, and we propose that SMC2 (or the condensin complex) is a novel molecular target for the treatment of MYCN-amplified neuroblastoma.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
Anti-N-Myc Mouse mAb (NCM II 100), liquid, clone NCM II 100, Calbiochem®